Applied DNA Sciences, Inc.
APDN
$2.51
-$0.24-8.73%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -53.31% | -26.43% | -8.51% | 16.43% | 66.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.31% | -26.43% | -8.51% | 16.43% | 66.41% |
| Cost of Revenue | -56.67% | -40.27% | -13.97% | 21.23% | 82.67% |
| Gross Profit | -46.43% | 9.49% | 2.93% | 7.47% | 40.76% |
| SG&A Expenses | 1.72% | -15.54% | -11.06% | -11.92% | -8.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.30% | -24.33% | -12.59% | -1.82% | 15.42% |
| Operating Income | -29.01% | 21.60% | 17.95% | 21.39% | 26.16% |
| Income Before Tax | 1.14% | -21.19% | 41.62% | 64.79% | 47.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.14% | -21.19% | 41.62% | 64.79% | 47.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2,469.23% | 3,514.29% | 2,092.59% | 814.29% | 160.94% |
| Net Income | 2.44% | -20.31% | 42.07% | 65.08% | 47.96% |
| EBIT | -29.01% | 21.60% | 17.95% | 21.39% | 26.16% |
| EBITDA | -33.00% | 24.36% | 20.61% | 24.48% | 30.12% |
| EPS Basic | 23.43% | 27.62% | 65.34% | 77.54% | 62.86% |
| Normalized Basic EPS | 23.44% | 27.02% | 62.58% | 76.12% | 63.71% |
| EPS Diluted | 23.19% | 27.40% | 65.19% | 77.42% | 62.74% |
| Normalized Diluted EPS | 23.44% | 27.02% | 62.58% | 76.12% | 63.71% |
| Average Basic Shares Outstanding | 28.50% | 45.79% | 56.15% | 52.20% | 40.21% |
| Average Diluted Shares Outstanding | 28.50% | 45.79% | 56.15% | 52.20% | 40.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
